ArticleEULAR rheumatology open2026
Effect of abatacept on bone in patients with psoriatic arthritis-results from a prospective interventional high-resolution imaging study (ABEPSA).
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Abatacept (ABA) is a selective costimulation modulator that inhibits T cell activation. It is approved for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). While its efficacy in RA is well established, its effect on structural joint damage in PsA remains uncertain. This study evaluated the effects of ABA on erosive and proliferative bone changes in PsA using high-resolution peripheral quantitative computed tomography (HR-pQCT) over 24 weeks. Methods: ABA bone effects in PsA with bone biomarkers is a prospective, single-arm, open-label, phase IV trial including patients with active PsA (≥2 swollen/tender joints and ≥1 hand joint erosion at baseline). Participants received weekly subcutaneous ABA (125 mg) for 24 weeks; those with good clinical response at week 12 continued treatment. Bone changes were assessed by HR-pQCT and magnetic resonance imaging (MRI) at baseline and week 24. The primary endpoint was change in erosion volume. Results: Fifteen patients (mean age 59.5 ± 9 years) were enrolled; 8 continued treatment through week 24. ABA led to a reduction in clinical disease activity. Imaging showed no new erosions or significant erosion progression, and no new structural entheseal lesions on HR-pQCT or MRI. Inflammatory MRI changes persisted in some cases. ABA was well tolerated with no new safety signals. Conclusions: ABA prevented new erosions and structural entheseal lesions over 24 weeks, indicating a potential osteoprotective effect. These results suggest ABA may modulate bone remodelling in PsA and help preserve joint structure alongside clinical improvements.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.